典型文献
New practice in semaglutide on type-2 diabetes and obesity:clinical evidence and expectation
文献摘要：
Obesity is an important risk factor of type 2 diabetes(T2D),which has become an important factor threatening human health.However,no perfect drug choice for obesity exists.Semaglutide is a kind of human glucagon-like peptide-1(GLP-1)analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism.GLP-1 can also delay stomach emptying and suppress appetite to help lose weight.This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
文献关键词：
中图分类号：
作者姓名：
Yalin Liu;Xianghang Luo
作者机构：
Department of Endocrinology,Endocrinology Research Center,Xiangya Hospital of Central South University,Changsha 410008,China;National Clinical Research Center for Geriatric Disorders,Xiangya Hospital of Central South University,Changsha 410008,China
文献出处：
引用格式：
[1]Yalin Liu;Xianghang Luo-.New practice in semaglutide on type-2 diabetes and obesity:clinical evidence and expectation)[J].医学前沿,2022(01):17-24
A类：
Semaglutide
B类：
New,practice,semaglutide,type,diabetes,obesity,clinical,evidence,Obesity,important,risk,T2D,which,has,become,threatening,human,health,However,no,perfect,drug,choice,exists,kind,glucagon,like,peptide,GLP,analog,that,promotes,insulin,secretion,while,inhibiting,through,glucose,concentration,dependent,mechanism,can,also,delay,stomach,emptying,suppress,appetite,help,lose,weight,This,review,summarizes,effect,establishes,expectations,future,trials,treatment
AB值：
0.665446
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
